The Justice Department’s declination for Balt SAS and Balt USA LLC is emerging as an early test of the department’s revised corporate-enforcement framework, with compliance observers arguing the case shows DOJ is trying to reward companies that report misconduct before investigators arrive.
DOJ declined to prosecute the French medical-device company, required disgorgement of $1,214,797. As well, the governement charged former Balt USA executive David Ferrera and Belgian consultant Marc Tilman over an alleged bribery scheme involving a physician at a French state-owned public hospital.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
